Kathiawad Today

Toll-Like Receptor Agonist Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Toll-Like Receptor Agonist Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

March 22
06:15 2023
Toll-Like Receptor Agonist Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Toll- Like Receptor Agonist pipeline constitutes 60+ key companies continuously working towards developing 60+ Toll- Like Receptor Agonist treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Toll- Like Receptor Agonist Overview

Toll-like receptors (TLRs) are protective immune sentries that sense pathogen-associated molecular patterns (PAMPs) such asunmethylated double-stranded DNA (CpG), single-stranded RNA (ssRNA), lipoproteins, lipopolysaccharide (LPS), and flagellin. Once these microbes have breached physical barriers such as the skin or intestinal tract mucosa, they are recognized by TLRs, which activate immune cell responses.

 

Toll- Like Receptor Agonist Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Toll- Like Receptor Agonist Market.

 

The Toll- Like Receptor Agonist Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Toll- Like Receptor Agonist Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Toll- Like Receptor Agonist treatment therapies with a considerable amount of success over the years. Toll- Like Receptor Agonist Key players such as – Pattern Pharma, Silverback Therapeutics, Apros Therapeutics, CureVac, Primmune Therapeutics, Oncovir, Highlight Therapeutics, PrEP Biopharm, InDex Pharmaceuticals, Protara Therapeutics, Idera Pharmaceuticals, and others, are developing therapies for the Toll- Like Receptor Agonist treatment 
  • Toll- Like Receptor Agonist Emerging therapies such as – P2PAR-100, SBT8230, APR003, CV8102, PRTX007, Poly ICLC, BO112, PrEP-001, Cobitolimod, TARA-002, Tilsotolimod, and others are expected to have a significant impact on the Toll- Like Receptor Agonist market in the coming years.   
  • In February 2022, Primmune Therapeutics presented interim data related to PRTX007, a novel, orally administered, small molecule toll-like receptor 7 (TLR7) specific agonist that is currently in Phase 1 development, at the Conference on Retroviruses and Opportunistic Infections (CROI). Oral administration of PRTX007 in this first-in-human study of healthy volunteers exhibited a favorable safety profile, rapid absorption and conversion to TLR7 agonist PRX034, and activation of the innate immune system without causing inflammation
  • In November 2021, InDex Pharmaceuticals initiated a randomised double-blind placebo-controlled Phase III clinical study to evaluate the efficacy and safety of Cobitolimod as an induction and maintenance therapy in participants with moderate to severe active left-sided Toll- Like Receptor Agonist
  • In March, 2021 Quibim, a global medical imaging analysis specialist, has joined Highlight Therapeutics, a clinical-stage company specialising in immuno-oncology, to assess the efficacy of new immune therapy treatments in advanced melanoma skin cancer using AI in a Phase II clinical trial in Spain
  • In September, 2020 Highlight Therapeutics has entered into a collaboration with a subsidiary of Merck & Co., under which the companies will focus on the Phase II evaluation of the combination of BO-112, Highlight’s lead program, and KEYTRUDA (pembrolizumab) anti-PD-1 therapy, in patients that have progressed on anti-PD-1-based therapy in refractory advanced malignant melanoma
  • In August 2017, FDA has granted orphan-drug designation for cobitolimod for treatment of Toll- Like Receptor Agonist in children, which may provide seven years of market exclusivity in this indication on the United States market

 

Route of Administration

Toll- Like Receptor Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Toll- Like Receptor Agonist Pipeline Therapeutics Assessment

  • Toll- Like Receptor Agonist Assessment by Product Type
  • Toll- Like Receptor Agonist By Stage and Product Type
  • Toll- Like Receptor Agonist Assessment by Route of Administration
  • Toll- Like Receptor Agonist By Stage and Route of Administration
  • Toll- Like Receptor Agonist Assessment by Molecule Type
  • Toll- Like Receptor Agonist by Stage and Molecule Type

 

DelveInsight’s Toll- Like Receptor Agonist Report covers around 60+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the Toll- Like Receptor Agonist Therapeutics Market include:

Key companies developing therapies for Toll- Like Receptor Agonist are – InDex Pharmaceuticals, Mologen, Exicure, Birdie Biopharmaceuticals, Seven and Eight Biopharmaceuticals, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Hoffman-La-Roche, Ascendis Pharma, Nektar therapeutics, BioNTech, Highlight Therapeutics, PrEP Biopharm, TriSalus Life Sciences,  Gilead Sciences, Tallac Therapeutics, Inc., ALX Oncology Holdings Inc., Checkmate Pharmaceuticals, AIM ImmunoTech, Scopus BioPharma, BrightPath Biotherapeutics, NapaJen Pharma, Ena Respiratory, Revelation Biosciences, Immune Design, Protara Therapeutics,  Galderma, Bolt Biotherapeutics, Jiangsu Hengrui Medicine Co., Novartis, Elicio Therapeutics, Statera BioPharma, and others.

 

Emerging Toll- Like Receptor Agonist Drugs Under Different Phases of Clinical Development Include:

  • P2PAR-100: Pattern Pharma
  • SBT8230: Silverback Therapeutics
  • APR003: Apros Therapeutics
  • CV8102: CureVac        
  • PRTX007: Primmune Therapeutics
  • Poly ICLC: Oncovir
  • BO112: Highlight Therapeutics
  • PrEP-001: PrEP Biopharm
  • Cobitolimod: InDex Pharmaceuticals
  • TARA-002: Protara Therapeutics
  • Tilsotolimod: Idera Pharmaceuticals

 

Get a Free Sample PDF Report to know more about Toll- Like Receptor Agonist Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/toll-like-receptor-agonist-pipeline-insight

 

Toll- Like Receptor Agonist Pipeline Analysis:

The Toll- Like Receptor Agonist pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Toll- Like Receptor Agonist with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Toll- Like Receptor Agonist Treatment.
  • Toll- Like Receptor Agonist key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Toll- Like Receptor Agonist Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Toll- Like Receptor Agonist market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Toll- Like Receptor Agonist product details are provided in the report. Download the Toll- Like Receptor Agonist pipeline report to learn more about the emerging Toll- Like Receptor Agonist therapies

 

Toll- Like Receptor Agonist Pipeline Market Drivers

  • TLR emerging as a potential therapeutic target
  • Increase in development of vaccines and other medications

 

Toll- Like Receptor Agonist Pipeline Market Barriers

  • Limited knowledge and research tools in Drug discovery approaches
  • Lack of Approved therapies in market

 

Scope of Toll- Like Receptor Agonist Pipeline Drug Insight    

  • Coverage: Global
  • Key Toll- Like Receptor Agonist Companies: Pattern Pharma, Silverback Therapeutics, Apros Therapeutics, CureVac, Primmune Therapeutics, Oncovir, Highlight Therapeutics, PrEP Biopharm, InDex Pharmaceuticals, Protara Therapeutics, Idera Pharmaceuticals, and others
  • Key Toll- Like Receptor Agonist Therapies: P2PAR-100, SBT8230, APR003, CV8102, PRTX007, Poly ICLC, BO112, PrEP-001, Cobitolimod, TARA-002, Tilsotolimod, and others
  • Toll- Like Receptor Agonist Therapeutic Assessment: Toll- Like Receptor Agonist current marketed and Toll- Like Receptor Agonist emerging therapies
  • Toll- Like Receptor Agonist Market Dynamics: Toll- Like Receptor Agonist market drivers and Toll- Like Receptor Agonist market barriers 

 

Request for Sample PDF Report for Toll- Like Receptor Agonist Pipeline Assessment and clinical trials

 

Table of Contents

1

Toll- Like Receptor Agonist Report Introduction

2

Toll- Like Receptor Agonist Executive Summary

3

Toll- Like Receptor Agonist Overview

4

Toll- Like Receptor Agonist- Analytical Perspective In-depth Commercial Assessment

5

Toll- Like Receptor Agonist Pipeline Therapeutics

6

Toll- Like Receptor Agonist Late Stage Products (Phase II/III)

7

Toll- Like Receptor Agonist Mid Stage Products (Phase II)

8

Toll- Like Receptor Agonist Early Stage Products (Phase I)

9

Toll- Like Receptor Agonist Preclinical Stage Products

10

Toll- Like Receptor Agonist Therapeutics Assessment

11

Toll- Like Receptor Agonist Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Toll- Like Receptor Agonist Key Companies

14

Toll- Like Receptor Agonist Key Products

15

Toll- Like Receptor Agonist Unmet Needs

16 

Toll- Like Receptor Agonist Market Drivers and Barriers

17

Toll- Like Receptor Agonist Future Perspectives and Conclusion

18

Toll- Like Receptor Agonist Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Toll- Like Receptor Agonist drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services